These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3835496)

  • 1. Scopolamine and the sensory conditioning of hallucinations.
    Warburton DM; Wesnes K; Edwards J; Larrad D
    Neuropsychobiology; 1985; 14(4):198-202. PubMed ID: 3835496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some additional data on the effects of scopolamine on habituation and conditioning in answer to Dr. Barton Meyers.
    Oliverio A
    Psychopharmacologia; 1968; 13(4):356-8. PubMed ID: 5722173
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of scopolamine injection during CS-US interval on conditioning.
    Kral PA
    Psychol Rep; 1971 Jun; 28(3):690. PubMed ID: 5091434
    [No Abstract]   [Full Text] [Related]  

  • 4. Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats.
    Ahlenius S; Ericson E
    J Neural Transm (Vienna); 2001; 108(4):415-30. PubMed ID: 11475009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scopolamine and Pavlovian fear conditioning in rats: dose-effect analysis.
    Anagnostaras SG; Maren S; Sage JR; Goodrich S; Fanselow MS
    Neuropsychopharmacology; 1999 Dec; 21(6):731-44. PubMed ID: 10633479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scopolamine administered before and after training impairs both contextual and auditory-cue fear conditioning.
    Rudy JW
    Neurobiol Learn Mem; 1996 Jan; 65(1):73-81. PubMed ID: 8673409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
    Barak S; Weiner I
    Neuropsychopharmacology; 2007 May; 32(5):989-99. PubMed ID: 16971898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats.
    Zhai H; Wu P; Chen S; Li F; Liu Y; Lu L
    Behav Pharmacol; 2008 May; 19(3):211-6. PubMed ID: 18469538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of muscarinic acetylcholine receptors in the ventral tegmental area disrupts food-related learning in rats.
    Sharf R; Ranaldi R
    Psychopharmacology (Berl); 2006 Jan; 184(1):87-94. PubMed ID: 16307293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of scopolamine on changes in regional cerebral blood flow during classical conditioning of the human eyeblink response.
    Bahro M; Molchan SE; Sunderland T; Herscovitch P; Schreurs BG
    Neuropsychobiology; 1999 May; 39(4):187-95. PubMed ID: 10343183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study.
    Thiel CM; Henson RN; Dolan RJ
    Neuropsychopharmacology; 2002 Aug; 27(2):282-92. PubMed ID: 12093602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of saccadic eye movements by scopolamine treatment.
    Oliva GA; Bucci MP; Fioravanti R
    Percept Mot Skills; 1993 Feb; 76(1):159-67. PubMed ID: 8451122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Learning impairment after three classes of agents which modify cholinergic function.
    Goldberg ME; Sledge K; Hefner M; Robichaud RC
    Arch Int Pharmacodyn Ther; 1971 Oct; 193(2):226-35. PubMed ID: 5119213
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of scopolamine on matching to sample paradigm and related tests in human subjects.
    Koller G; Satzger W; Adam M; Wagner M; Kathmann N; Soyka M; Engel R
    Neuropsychobiology; 2003; 48(2):87-94. PubMed ID: 14504417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous scopolamine is potently self-administered in drug-naive mice.
    Rasmussen T; Fink-Jensen A
    Neuropsychopharmacology; 2000 Jan; 22(1):97-9. PubMed ID: 10633495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracerebral scopolamine administration attenuates Pavlovian heart rate conditioning in the rabbit.
    Powell DA; Buchanan S; Hernández L
    Pavlov J Biol Sci; 1985; 20(3):116-23. PubMed ID: 4034263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scopolamine impairs acquisition and facilitates consolidation of fear conditioning: differential effects for tone vs context conditioning.
    Young SL; Bohenek DL; Fanselow MS
    Neurobiol Learn Mem; 1995 Mar; 63(2):174-80. PubMed ID: 7663891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of hippocampal GABA(A) and muscarinic receptors in consolidation of context memory and context-shock association in contextual fear conditioning: a double dissociation study.
    Chang SD; Liang KC
    Neurobiol Learn Mem; 2012 Jul; 98(1):17-24. PubMed ID: 22543193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free operant and discrete trial performance of mice in the nine-hole box apparatus: validation using amphetamine and scopolamine.
    Bensadoun JC; Brooks SP; Dunnett SB
    Psychopharmacology (Berl); 2004 Jul; 174(3):396-405. PubMed ID: 14985934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.